

Mosaiques Diagnostics: empowering proteome analysis and personalized precision medicine




Harald Mischak

Background

- **Proteins** are active key players in every organism that drive normal and pathological processes.
- **Proteins are responsible for disease-specific processes**, and can be targeted with drugs.
- **Proteome analysis enables** optimal diagnosis, prognosis, and selection of ideal therapeutic intervention.
- **Combinatorial Approach:** Rationale therapeutic targets, monitoring and stratification biomarkers and appropriate drugs, ultimately enable ideal and personalized patient management.

Early diagnosis improves outcome




death

Human proteome database

Clinical data, Patients history

Age
Gender
Urinary albumin/creatinine
Cholesterole (mmol/l)
Creatinine (micromol/l)


Urinary proteomics data




Database




Sequence information




Tissue proteomics data



Biomarker selection




Statistics




Original Article

Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis

Justyna Siwy¹, Petra Züribig¹, Angel Argiles², Joachim Beige³, Marion Haubitz⁴, Joachim Jankowski^{5,6}, Bruce A. Julian⁷, Peter G. Linde⁸, David Marx⁹, Harald Mischak^{1,10}, William Mullen¹⁰, Jan Novak⁷, Alberto Ortiz¹¹, Frederik Persson¹², Claudia Pontillo^{1,13}, Peter Rossing^{12,14,15}, Harald Rupprecht¹⁶, Joost P. Schanstra^{17,18}, Antonia Vlahou¹⁹ and Raymond Vanholder²⁰



Fields of Application (Sensitivity / Specificity)



- **Proteome analysis is already in use in clinical trials and patient management, guiding personalized intervention**
- **Mosaiques Diagnostics is the worldwide leader in clinical proteomics, with several products in the market and a Letter of Support from the US-FDA**
- **Substantial support from the European Commission enabled development of the technology and applications**

PCaProTreat



BioMedBC



PROTOCLIN

IMPROVEMENT OF TOOLS AND PORTABILITY OF MASS SPECTROMETRY-BASED CLINICAL PROTEOMICS AS APPLIED TO CHRONIC KIDNEY DISEASE

FP7 and H2020 Funding

